Trial Profile
A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary) ; Moxifloxacin
- Indications Atherosclerosis; Dyslipidaemias
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 26 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.